EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-788-9043
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.65 million
Profitability
Miscellaneous
Employees11
Next Earnings Date3/22/2019 (Estimated)
OptionableNot Optionable
Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions
What is Eyegate Pharmaceuticals' stock symbol?
Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."
How were Eyegate Pharmaceuticals' earnings last quarter?
Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) released its quarterly earnings results on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The specialty pharmaceutical company earned $0.32 million during the quarter, compared to analysts' expectations of $0.19 million. Eyegate Pharmaceuticals had a negative return on equity of 111.46% and a negative net margin of 649.70%. View Eyegate Pharmaceuticals' Earnings History.
When is Eyegate Pharmaceuticals' next earnings date?
What price target have analysts set for EYEG?
1 brokerages have issued 1-year price objectives for Eyegate Pharmaceuticals' shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Eyegate Pharmaceuticals' share price to reach $6.00 in the next year. This suggests a possible upside of 1,328.6% from the stock's current price. View Analyst Price Targets for Eyegate Pharmaceuticals.
What is the consensus analysts' recommendation for Eyegate Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyegate Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyegate Pharmaceuticals.
Has Eyegate Pharmaceuticals been receiving favorable news coverage?
News articles about EYEG stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eyegate Pharmaceuticals earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days.
Who are some of Eyegate Pharmaceuticals' key competitors?
Some companies that are related to Eyegate Pharmaceuticals include Processa Pharmaceuticals (PCSA), Ovid Therapeutics (OVID), Medicure (MCUJF), Aravive (ARAV), Sesen Bio (SESN), Apricus Biosciences (APRI), Tetraphase Pharmaceuticals (TTPH), NewLink Genetics (NLNK), Teligent (TLGT), Akari Therapeutics (AKTX), Agile Therapeutics (AGRX), Nemus Bioscience (NMUS), Selecta Biosciences (SELB), Tiziana Life Sciences (TLSA) and Eyenovia (EYEN).
What other stocks do shareholders of Eyegate Pharmaceuticals own?
Who are Eyegate Pharmaceuticals' key executives?
Eyegate Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen From, Pres, CEO & Director (Age 56)
- Dr. Barbara M. Wirostko, Chief Medical Officer (Age 53)
- Mr. Michael P. Manzo, VP of Engineering (Age 60)
- Ms. Sarah Romano, Chief Financial Officer
- Dr. MaryJane Rafii Ph.D., Consultant
When did Eyegate Pharmaceuticals IPO?
(EYEG) raised $5 million in an IPO on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.
Who are Eyegate Pharmaceuticals' major shareholders?
Eyegate Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (0.22%) and Virtu Financial LLC (0.16%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Sarah Romano and Stephen From. View Institutional Ownership Trends for Eyegate Pharmaceuticals.
Which major investors are buying Eyegate Pharmaceuticals stock?
EYEG stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Acadian Asset Management LLC. Company insiders that have bought Eyegate Pharmaceuticals stock in the last two years include Armistice Capital Master Fund, Sarah Romano and Stephen From. View Insider Buying and Selling for Eyegate Pharmaceuticals.
How do I buy shares of Eyegate Pharmaceuticals?
Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eyegate Pharmaceuticals' stock price today?
One share of EYEG stock can currently be purchased for approximately $0.42.
How big of a company is Eyegate Pharmaceuticals?
Eyegate Pharmaceuticals has a market capitalization of $18.39 million and generates $1.65 million in revenue each year. The specialty pharmaceutical company earns $-10,810,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Eyegate Pharmaceuticals employs 11 workers across the globe.
What is Eyegate Pharmaceuticals' official website?
How can I contact Eyegate Pharmaceuticals?
Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-9043.
MarketBeat Community Rating for Eyegate Pharmaceuticals (NASDAQ EYEG)
MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days.
